[{"address1": "117 Kendrick Street", "address2": "Suite 500", "city": "Needham", "state": "MA", "zip": "02494", "country": "United States", "phone": "781 292 4200", "website": "https://www.verastem.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.", "fullTimeEmployees": 78, "companyOfficers": [{"maxAge": 1, "name": "Mr. Daniel W. Paterson", "age": 64, "title": "President, CEO & Director", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 1027890, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Calkins", "age": 37, "title": "Chief Financial Officer", "yearBorn": 1988, "fiscalYear": 2024, "totalPay": 471690, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael Glen Kauffman M.D., Ph.D.", "age": 62, "title": "President of Development & Director", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 105000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert A. Weinberg Ph.D.", "title": "Co-Founder & Chair of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michelle  Detwiler M.D., Ph.D.", "age": 49, "title": "Co-Founder", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jonathan  Pachter Ph.D.", "age": 67, "title": "Chief Scientific Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 238176, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Julissa  Viana", "title": "Vice President of Corporate Communications & Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark J. Wanda", "title": "Senior VP of Legal & Chief Compliance Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cathy  Carew", "title": "Chief Organizational Effectiveness Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nate  Sanburn", "title": "Chief Business Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 7, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1767225600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 7.87, "open": 8.12, "dayLow": 7.74, "dayHigh": 8.35, "regularMarketPreviousClose": 7.87, "regularMarketOpen": 8.12, "regularMarketDayLow": 7.74, "regularMarketDayHigh": 8.35, "payoutRatio": 0.0, "beta": 0.436, "forwardPE": -4.6739907, "volume": 2171493, "regularMarketVolume": 2171493, "averageVolume": 2338130, "averageVolume10days": 2100050, "averageDailyVolume10Day": 2100050, "bid": 6.15, "ask": 10.18, "bidSize": 2, "askSize": 2, "marketCap": 586741248, "fiftyTwoWeekLow": 4.01, "fiftyTwoWeekHigh": 11.25, "allTimeHigh": 225.84, "allTimeLow": 2.1, "priceToSalesTrailing12Months": 43.85539, "fiftyDayAverage": 8.8038, "twoHundredDayAverage": 7.52345, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 471956096, "profitMargins": 0.0, "floatShares": 51277963, "sharesOutstanding": 75319800, "sharesShort": 16721345, "sharesShortPriorMonth": 19141071, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.222, "heldPercentInsiders": 0.0059100003, "heldPercentInstitutions": 0.87160003, "shortRatio": 7.73, "shortPercentOfFloat": 0.2227, "impliedSharesOutstanding": 75319800, "bookValue": -0.233, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -241106000, "trailingEps": -4.28, "forwardEps": -1.66667, "lastSplitFactor": "1:12", "lastSplitDate": 1685577600, "enterpriseToRevenue": 35.276, "enterpriseToEbitda": -2.953, "52WeekChange": 0.4588015, "SandP52WeekChange": 0.19362879, "quoteType": "EQUITY", "currentPrice": 7.79, "targetHighPrice": 20.0, "targetLowPrice": 14.0, "targetMeanPrice": 16.125, "targetMedianPrice": 15.5, "recommendationMean": 1.11111, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 137706000, "totalCashPerShare": 2.062, "ebitda": -159807008, "totalDebt": 89477000, "quickRatio": 2.422, "currentRatio": 2.58, "totalRevenue": 13379000, "revenuePerShare": 0.221, "returnOnAssets": -0.66056997, "returnOnEquity": -28.88708, "grossProfits": 11391000, "freeCashflow": -80609624, "operatingCashflow": -132654000, "grossMargins": 0.85141, "ebitdaMargins": 0.0, "operatingMargins": -3.62169, "financialCurrency": "USD", "symbol": "VSTM", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1327674600000, "shortName": "Verastem, Inc.", "longName": "Verastem, Inc.", "postMarketChangePercent": 0.7650819, "postMarketPrice": 7.8496, "postMarketChange": 0.059599876, "regularMarketChange": -0.0799999, "regularMarketDayRange": "7.74 - 8.35", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 2338130, "fiftyTwoWeekLowChange": 3.7799997, "fiftyTwoWeekLowChangePercent": 0.9426433, "fiftyTwoWeekRange": "4.01 - 11.25", "fiftyTwoWeekHighChange": -3.46, "fiftyTwoWeekHighChangePercent": -0.30755556, "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1768004329, "regularMarketTime": 1767992400, "exchange": "NCM", "messageBoardId": "finmb_115881768", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "fiftyTwoWeekChangePercent": 45.88015, "earningsTimestamp": 1762263000, "earningsTimestampStart": 1762263000, "earningsTimestampEnd": 1762263000, "earningsCallTimestampStart": 1762261200, "earningsCallTimestampEnd": 1762261200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -4.28, "epsForward": -1.66667, "epsCurrentYear": -2.725, "priceEpsCurrentYear": -2.8587158, "fiftyDayAverageChange": -1.0137997, "fiftyDayAverageChangePercent": -0.11515479, "twoHundredDayAverageChange": 0.26655006, "twoHundredDayAverageChangePercent": 0.03542923, "priceToBook": -33.433475, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.1 - Strong Buy", "cryptoTradeable": false, "regularMarketChangePercent": -1.01652, "regularMarketPrice": 7.79, "displayName": "Verastem", "trailingPegRatio": null, "__fetch_time": "2026-01-10"}]